Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx’s OvPlex

Premium
HealthLinx, in collaboration with ARL Pathology, this week launched OvPlex, an early-stage test for ovarian cancer detection, in Australia. 
 
OvPlex detects the presence of five protein biomarkers linked to ovarian caner in patient blood samples. HealthLinx claims that its biomarker panel can detect cancer with greater accuracy than the biomarker CA125.
 
In clinical trials, the test yielded 89.2 percent sensitivity and 93.9 percent specificity.
 
The test will be available through general practitioners in Melbourne before being rolled out to other states in Australia. The test will cost $200 and results will be available in 14 days.
 
HealthLinx said in a statement that it is continuing research and development on a next-generation ovarian cancer diagnostic with improved accuracy.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.